(P024) Predictors of Radiation-Induced Skin Toxicity: Data From a Prospective Cohort Receiving Breast Radiation

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In this prospectively followed cohort of breast cancer patients receiving RT to the intact breast, novel predictors for more severe skin toxicity were identified, including PR-negative status, invasive ductal histology, and receipt of chemotherapy, as well as known risk factors, including BMI and fractionation scheme.

Jean Wright, MD, Cristiane Takita, MD, Isildinha M. Reis, Wei Zhao, MD, BS, Eunkyung Lee, MS, Jennifer Hu, PhD; Johns Hopkins University; University of Miami

PURPOSE/OBJECTIVES: Breast radiation (RT) is generally well tolerated, but acute skin toxicity is a common side effect that can impact receipt of treatment and quality of life. We sought to identify predictors of radiation-induced skin toxicity in a racially and ethnically diverse cohort of women receiving RT to the intact breast.

MATERIALS AND METHODS: We evaluated the first 392 patients in an ongoing prospective study assessing radiation-induced skin toxicity in patients receiving breast RT. We recorded patient demographics, body mass index (BMI), and disease and treatment characteristics. Skin toxicity grade using Common Terminology Criteria for Adverse Events (CTCAE) and a modified scale capturing moist desquamation were captured at Week 3 and at RT completion. Logistic regression analyses were conducted to evaluate the effect of potential predictors on the risk of skin toxicity.

RESULTS: A total of 20.2% self-identified as African American, 15% self-identified as non-Hispanic white, 61.5% self-identified as Hispanic white, and 3.3% self-identified as other. Mean age was 56.2 years, and 74.2% had a body mass index (BMI) ≥ 25. Disease was stage 0 in 20.2% (in situ), I in 49.2%, and II or III in 30.6%. Further, 17.2% of patients were treated with hypofractionated regimens to the breast +/− regional nodes with a whole-breast dose of < 45 Gy, and 82.8% of patients were treated with conventionally fractionated regimens with a dose of ≥ 45 Gy. On multivariate analysis, both scales identified higher BMI, higher disease stage, invasive ductal histology, progesterone receptor (PR)-negative status, and conventionally fractionated regimens with total radiation dose ≥ 45 Gy as predictors for higher skin toxicity grade. The modified scale also identified larger breast volume as a predictor for moist desquamation, and the CTCAE scale identified chemotherapy use as a predictor for grade 2/3 skin toxicity.

CONCLUSION: In this prospectively followed cohort of breast cancer patients receiving RT to the intact breast, novel predictors for more severe skin toxicity were identified, including PR-negative status, invasive ductal histology, and receipt of chemotherapy, as well as known risk factors, including BMI and fractionation scheme.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content